Sale Of Goods was Teva Pharmaceutical Industries’s largest product and service line in fiscal 2025, bringing in $14.61B of $17.26B (85%).
| Product and Service | FY 2008 | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sale Of Goods | $12.77B | $12.98B | — | $14.61B | ||||||||||||||
| Generics | — | — | — | — | ||||||||||||||
| Generic Products (Including Otc & Biosimilars) | — | — | $9.46B | — | ||||||||||||||
| Branded | — | — | — | — | ||||||||||||||
| Innovative Products | — | — | — | — | ||||||||||||||
| Other | $428.00M | $1.82B | — | $1.51B | ||||||||||||||
| Other Products | — | — | $1.38B | — | ||||||||||||||
| Distribution | $1.52B | — | $1.58B | — | ||||||||||||||
| Distribution Service | — | — | — | — | ||||||||||||||
| Anda | — | — | — | — | ||||||||||||||
| Austedo | — | — | $1.69B | — | ||||||||||||||
| Speciality Respiratory Products | — | — | — | — | ||||||||||||||
| Product & Service Other | — | — | $745.00M | — | ||||||||||||||
| Copaxone | — | $591.00M | $503.00M | $468.00M | ||||||||||||||
| Active Pharmaceutical Ingredients | — | — | — | — | ||||||||||||||
| Proair | — | — | — | — | ||||||||||||||
| Respiratory Product | — | — | $244.00M | — | ||||||||||||||
| Ajovy | — | $434.00M | $507.00M | — | ||||||||||||||
| Bendeka & Treanda | — | — | $168.00M | — | ||||||||||||||
| Licensing Arrangements | $212.00M | — | $173.00M | $678.00M | ||||||||||||||
| Uzedy | — | $23.00M | $117.00M | — | ||||||||||||||
| Bio Generics | — | — | — | — | ||||||||||||||
| Total | $14.93B | $15.85B | $16.56B | $17.26B |
Teva Pharmaceutical Industries brought in $17.26B from its four product and service lines in fiscal 2025, the year ended December 31, 2025. Teva Pharmaceutical Industries regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $16.56B. Sale Of Goods was the largest at $14.61B (84.6%), ahead of Other at $1.51B (8.7%) and Licensing Arrangements at $678.00M (3.9%). The remaining line, Copaxone, brought in $468.00M.
Compared with fiscal 2024, Licensing Arrangements grew 291.9% to $678.00M, while Copaxone fell 7.0% to $468.00M.
Teva Pharmaceutical Industries stopped reporting Generic Products (Including Otc & Biosimilars) ($9.46B in fiscal 2024), Austedo ($1.69B in fiscal 2024), Distribution ($1.58B in fiscal 2024) and six others as separate lines.
United States was Teva Pharmaceutical Industries’s largest segment in fiscal 2025, bringing in $9.19B of $17.26B (53%).
| Segment | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| North America | — | — | — | — | ||||||
| United States | $7.00B | $7.73B | $8.03B | $9.19B | ||||||
| Europe | $4.53B | $4.84B | $5.10B | $5.04B | ||||||
| International Markets | $2.35B | $2.35B | $2.46B | $2.16B | ||||||
| Other Activities | $1.05B | $926.00M | $944.00M | $870.00M | ||||||
| Total | $14.93B | $15.85B | $16.54B | $17.26B |
Teva Pharmaceutical Industries brought in $17.26B from its four segments in fiscal 2025, the year ended December 31, 2025. That was up 4.3% from $16.54B in fiscal 2024. United States was the largest at $9.19B (53.2%), ahead of Europe at $5.04B (29.2%) and International Markets at $2.16B (12.5%). The remaining segment, Other Activities, brought in $870.00M.
Compared with fiscal 2024, United States grew fastest, up 14.3% to $9.19B, while International Markets fell the most, down 12.2% to $2.16B. From fiscal 2022 to 2025, combined revenue from these segments grew from $14.93B to $17.26B, a compound annual growth rate of 5.0%. United States' share of the total rose from 46.9% to 53.2%.
Branded was Teva Pharmaceutical Industries’s largest revenue line in fiscal 2017, bringing in $7.91B of $21.53B (37%).
| Product Line | FY 2009 | FY 2010 | FY 2011 | FY 2014 | FY 2017 |
|---|---|---|---|---|---|
| Generics | — | — | |||
| Branded | $8.56B | $7.91B | |||
| Branded Cns | $5.58B | $4.43B | |||
| Branded Cnscopaxone | $4.24B | $3.80B | |||
| Branded Respiratory Products | — | $1.27B | |||
| Other Revenues | — | — | |||
| Branded Oncology Treanda | $767.00M | $658.00M | |||
| Other Otcproducts | — | — | |||
| Branded Respiratory Proair | — | $501.00M | |||
| Other Branded Products | $344.00M | $657.00M | |||
| Branded Womens Health Products | $504.00M | $426.00M | |||
| Branded Oncology Products | — | $1.14B | |||
| Branded Cnsprovigil | — | — | |||
| Branded Respiratory Qvar | $286.00M | $361.00M | |||
| Branded Cnsazilect | — | $170.00M | |||
| Ninlaro1 | — | $150.00M | |||
| Branded Cnsnuvigil | — | $61.00M | |||
| Total | $20.27B | $21.53B |
Teva Pharmaceutical Industries brought in $21.53B from its 13 revenue lines in fiscal 2017, the year ended December 31, 2017. Teva Pharmaceutical Industries regrouped these revenue lines after fiscal 2014, so the total does not compare directly with that year's $20.27B. Branded was the largest at $7.91B (36.8%), ahead of Branded Cns at $4.43B (20.6%) and Branded Cnscopaxone at $3.80B (17.7%). The other 10 revenue lines brought in $5.39B combined.
Compared with fiscal 2014, the previous year with figures, Other Branded Products grew fastest, up 91.0% to $657.00M, while Branded Cns fell the most, down 20.6% to $4.43B.
Teva Pharmaceutical Industries began breaking out Ninlaro1 in fiscal 2017, when it brought in $150.00M.
Teva Pharmaceutical Industries (TEVA) reports its revenue by product and service, by segment and by product line. In fiscal 2025, Sale Of Goods was its largest product and service line, bringing in $14.61B (84.6% of the total), followed by Other at $1.51B (8.7%).
Sale Of Goods was Teva Pharmaceutical Industries' largest product and service line in fiscal 2025, bringing in $14.61B, or 84.6% of the $17.26B total across its four product and service lines.
United States was Teva Pharmaceutical Industries' largest segment in fiscal 2025, bringing in $9.19B, or 53.2% of the $17.26B total across its four segments.
Branded was Teva Pharmaceutical Industries' largest revenue line in fiscal 2017, bringing in $7.91B, or 36.8% of the $21.53B total across its 13 revenue lines.
Among Teva Pharmaceutical Industries' segments that make up at least 2% of revenue, United States grew fastest in fiscal 2025, up 14.3% from $8.03B to $9.19B.
Every figure comes from Teva Pharmaceutical Industries' annual financial filings, as reported. Each line keeps the name Teva Pharmaceutical Industries gives it, and years follow its fiscal calendar.
Teva Pharmaceutical Industries' revenue by product and service goes back to fiscal 2008, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.